The international Phase 2 ADCAP trial for AON-D21 in severe community-acquired pneumonia has completed enrollment.
Category: Allgemein
US IND received and extension of the ADCAP trial to 150 patients.
After pre-scheduled review of the safety and efficacy data of the first 40 patients, the Data Monitoring Committee has recommended to continue enrolment into the ADCAP trial.
Pre-scheduled safety review after 12 patients: Data Monitoring Committee recommends continuation of the trial as planned.
First patient dosed in Phase 2 ADCAP trial to treat severe cases of pneumonia. The double-blind, placebo-controlled trial will recruit 100 patients in five European countries.
First closing of Series B financing round
Multiple ascending dose study with AON-D21 completed
Single ascending dose study with AON-D21 completed
First healthy volunteer dosed with AON-D21
German Medicines Agency BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) approved the First-in-Human study with AON-D21